Genmab A/S (NASDAQ:GMAB) Releases Earnings Results, Beats Estimates By $0.20 EPS

Genmab A/S (NASDAQ:GMAB) posted its quarterly earnings data on Thursday. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.36 by $0.20, Zacks reports. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.20 billion. Genmab A/S had a net margin of 16.97% and a return on equity of 13.96%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
• Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
• The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
• Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
• Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.

Genmab A/S Trading Up 1.7%

Shares of GMAB stock traded up $0.89 on Friday, reaching $53.63. 7,827,783 shares of the stock were exchanged, compared to its average volume of 6,032,240. The stock has a market cap of $33.47 billion, a P/E ratio of 41.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.73. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a 50 day moving average of $39.18 and a two-hundred day moving average of $31.11. Genmab A/S has a 1-year low of $23.62 and a 1-year high of $59.97.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on GMAB shares. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. HC Wainwright increased their price target on Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Guggenheim increased their price target on Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Morgan Stanley raised their price objective on Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a report on Friday, October 30th. Finally, New Street Research set a $43.00 price objective on Genmab A/S in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.61.

About Genmab A/S

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.